Gout: Its not all crystal clear Robert L. Wortmann, M.D. Robert L. Wortmann, M.D. Department of Internal Medicine Department of Internal Medicine The University of Oklahoma College of The University of Oklahoma College of Medicine, Tulsa Medicine, Tulsa
53
Embed
Gout: Its not all crystal clear Robert L. Wortmann, M.D. Department of Internal Medicine The University of Oklahoma College of Medicine, Tulsa.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Gout:Its not all crystal clear
Robert L. Wortmann, M.D.Robert L. Wortmann, M.D.Department of Internal MedicineDepartment of Internal Medicine
The University of Oklahoma College of Medicine, TulsaThe University of Oklahoma College of Medicine, Tulsa
But it should be!!!!!!!!
Name another disease thatName another disease that
-the cause and pathophysiology are -the cause and pathophysiology are so so well undeerstoodwell undeerstood
-the diagnosis can be made with -the diagnosis can be made with such certaintysuch certainty
-available therapies can be so -available therapies can be so effectiveeffective
Objectives
Review the clinical features of goutReview the clinical features of gout Review the rationale for therapies of gouty Review the rationale for therapies of gouty
arthritis and the underlying hyperuricemiaarthritis and the underlying hyperuricemia Answer questionsAnswer questions
CorticosteroidsCorticosteroidsInhibit PGEInhibit PGE22 and LTB and LTB44
Stabilize lysosomal membranesStabilize lysosomal membranes ACTHACTH
Agonist of the leukocyte melatonin Agonist of the leukocyte melatonin receptor-3receptor-3
The The secretsecret is is not whatnot what is is used, but used, but how quicklyhow quickly therapy is initiated after therapy is initiated after the attack begins!the attack begins!
Stage III
Chronic Gouty ArthritisChronic Gouty Arthritis Tophi on physical examTophi on physical exam Chronic degenerative arthritisChronic degenerative arthritis
Clinical Course of Classic Gout
Antihyperuricemic Therapy
1.1. Treat acute attack until resolvedTreat acute attack until resolved
2.2. Colchicine or NSAID for prophylaxisColchicine or NSAID for prophylaxis
3.3. Xanthine oxidase inhibitor or uricosuricXanthine oxidase inhibitor or uricosuric
4.4. Address other problemsAddress other problems HypertensionHypertension ObesityObesity AlcoholismAlcoholism
Goal of Antihyperuricemic Therapy Serum Urate Serum Urate 5.0 mg/dl! 5.0 mg/dl! Lowering serum urate to > Lowering serum urate to >
7.0 mg/dl does not reverse 7.0 mg/dl does not reverse the problem. It only slows the problem. It only slows the rate of progression.the rate of progression.
Candidates for Uricosuric Agents Compliant patientsCompliant patients Under 60 years oldUnder 60 years old Good renal function*Good renal function* No ASANo ASA
Can use 81 mg but sould be taken 6 hours after Can use 81 mg but sould be taken 6 hours after the uricosuricthe uricosuric
No history of kidney stonesNo history of kidney stones Underexcrete uric acidUnderexcrete uric acid
Candidates for Allopurinol Everyone except thoseEveryone except those
Sensitive to itSensitive to it Taking azathioprineTaking azathioprine
Allopurinol hasAllopurinol has Once-a-day dosageOnce-a-day dosage Few drug-drug interactionsFew drug-drug interactions Effective in renal failure*Effective in renal failure* Can be used in overproducers and Can be used in overproducers and
underproducersunderproducers
Although there have been no new urate-lowering therapies available to treat gout since 1964, there will be soon.
Uricase PEG20Uricase PEG20 II PEG urate oxidasePEG urate oxidase
oxypurinoloxypurinol IIII XOIXOI
Y-700Y-700 I-III-II XOIXOI
KT-433KT-433 IIII UricosuricUricosuric
Febuxostat
A nonpurine, selective inhibitor of xanthine oxidase in phase III studies for the A nonpurine, selective inhibitor of xanthine oxidase in phase III studies for the treatment of hyperuricemia in patients with gouttreatment of hyperuricemia in patients with gout
Current data supportCurrent data support
Potent inhibition with significant urate reductionPotent inhibition with significant urate reduction
Ability to administer in renal insufficiencyAbility to administer in renal insufficiency11 and mild or moderate hepatic and mild or moderate hepatic insufficiency with no dosage adjustmentsinsufficiency with no dosage adjustments22
Safe, effective and well tolerated in limited data of allopurinol intolerant Safe, effective and well tolerated in limited data of allopurinol intolerant patientspatients33
N
N
NH
N
OH
Allopurinol
1. Swan et al. Arthritis Rheum. 2003;48(9):S529.2. Khosravan et al. Arthritis Rheum. 2004;50(9):S806.3. Becker et al. Arthritis Rheum. 2004;50(9):S803.
Febuxostat
O
NC
N
CO2HS
CH3
CH3
H3C
Febuxostat Phase III Clinical Trial
Study design: randomized, double-blind, 52 Study design: randomized, double-blind, 52 week, multicenter trial. week, multicenter trial.
Objective: to assess safety and efficacy (vs. Objective: to assess safety and efficacy (vs. allopurinol) of daily febuxostat allopurinol) of daily febuxostat administration in lowering sUA levels in administration in lowering sUA levels in subjects with gout and hyperuricemia (sUA subjects with gout and hyperuricemia (sUA 8.0 mg/dL).8.0 mg/dL).
*p<0.05 for each febuxostat group vs. allopurinol group
Proportion of Subjects with sUA <6.0 mg/dL (ITT Subjects)
Becker et al. ACR/ARHP Program Book Supplement. 2004;L18.
Why do people still suffer from gout?
Despite the fact that we understand its cause Despite the fact that we understand its cause and underlying pathophysiologyand underlying pathophysiology
Despite the fact that we can diagnosis it Despite the fact that we can diagnosis it with absolute certaintywith absolute certainty
Despite the fact that we have such rational Despite the fact that we have such rational and effective therapiesand effective therapies